A Phase 4 Decentralized Pilot Study With Wearable Technology in Cystic Fibrosis Subjects 18 Years of Age and Older Taking Commercial Elexacaftor/Tezacaftor/Ivacaftor
Latest Information Update: 16 Nov 2022
At a glance
- Drugs Elexacaftor/ivacaftor/tezacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 03 Nov 2022 According to a Vertex media release, data from this study will be presented at the 2022 North American Cystic Fibrosis Conference.
- 18 Jan 2022 Status changed from active, no longer recruiting to completed.
- 29 Oct 2021 Status changed from recruiting to active, no longer recruiting.